The future of pharmaceutical R and D: Somewhere between open and reverse innovation?

Future Medicinal Chemistry

Volumn 2, Issue 9, 2010, Pages 1399-1403

  Talaga, Patrice ^a  

^a Preclinical CNS Research   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NON PRESCRIPTION DRUG;

DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; DRUG RESEARCH; ECONOMIC ASPECT; NOTE; PRIORITY JOURNAL; ORGANIZATION; RESEARCH;

DRUG INDUSTRY; ORGANIZATIONAL INNOVATION; RESEARCH;

EID: 77956566104     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.213     Document Type: Note

References (9)

1. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
2. Chesbrough HW. Open innovation: the new imperative for creating and profting from technology. Harvard Business School Press, Boston, MA, USA (2003).
3. Talaga P. Open innovation: share or die. Drug Discov. Today 14, 1003-1005 (2009).
4. Yamaguchi E. Shionogi/Purdue strategic discovery alliance with synchronicity and serendipity-case study of open innovation. Les Nouvelles 72-78 (2009).
5. Hunter J, Stephens S. Is open innovation the way forward for big pharma? Nat. Rev. Drug Discov. 9, 87-88 (2010).
6. Vargas G, Boutouyrie B, Ostrowitzki S, Santarelli L. Arguments against precompetitive collaboration. Clin. Pharmacol. Ther. 87, 527-529 (2010).
7. Wagner JA, Prince M, Wright EC et al. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration. Clin. Pharmacol. Ther. 87, 539-542 (2010).
8. Immelt JR, Govindarajan V, Trimble C. How GE is disrupting itself. Harv. Bus. Rev. 3-11 (2009).
9. Hughes B. New and Analysis. An audience with Jingwu Zang. Nat. Rev. Drug Discov. 8, 352 (2009).